

Amicus Therapeutics Inc (FOLD) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/A003F789855EN.html>

Date: October 2021

Pages: 59

Price: US\$ 125.00 (Single User License)

ID: A003F789855EN

Abstracts

Amicus Therapeutics Inc (FOLD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Amicus Therapeutics Inc (Amicus Therapeutics) is a biotechnology company, which focuses on the research, development and commercialization of small molecule drugs and orally administered drugs known as pharmacological chaperones for the treatment of rare and orphan diseases. The company's lead product, migalastat HCl, a small molecule, is indicated for the treatment of Fabry disease. The other products in the pipeline include ATB200/AT2221 for the treatment of Pompe disease, Fabry disease, and other lysosomal storage disorders; migalastat for other conditions; and enzyme replacement therapies for other rare diseases. It has presence in the US, the UK, Ireland, France, the Netherlands, Germany, Spain, Italy and Japan. Amicus Therapeutics is headquartered in Cranbury, New Jersey, the US.

Amicus Therapeutics Inc Key Recent Developments

Aug 05,2021: Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates

Jul 27,2021: Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021

Jun 14,2021: Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of

Directors

May 10,2021: Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates

May 06,2021: Amicus Therapeutics Appoints S?bastien Martel as Senior Vice President of Strategy and Business Development

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage,

financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Amicus Therapeutics Inc - Key Facts
Amicus Therapeutics Inc - Key Employees
Amicus Therapeutics Inc - Key Employee Biographies
Amicus Therapeutics Inc - Major Products and Services
Amicus Therapeutics Inc - History
Amicus Therapeutics Inc - Company Statement
Amicus Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Amicus Therapeutics Inc - Business Description
Geographical Segment: Ex-US
Performance
Geographical Segment: The US
Performance
R&D Overview
Amicus Therapeutics Inc - Corporate Strategy
Amicus Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Amicus Therapeutics Inc - Strengths
Amicus Therapeutics Inc - Weaknesses
Amicus Therapeutics Inc - Opportunities
Amicus Therapeutics Inc - Threats
Amicus Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Amicus Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 05, 2021: Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates

Jul 27, 2021: Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021

Jun 14, 2021: Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

May 10, 2021: Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates

May 06, 2021: Amicus Therapeutics Appoints S?bastien Martel as Senior Vice President of Strategy and Business Development

May 05, 2021: Amicus Therapeutics announces upcoming presentations at the American Society of Gene & Cell Therapy 24th annual meeting

Apr 28, 2021: Amicus Therapeutics recognized as a great place to work in Europe

Feb 18, 2021: Amicus Therapeutics to Present at Upcoming Investor Conferences

Feb 17, 2021: Amicus Therapeutics to Announce Full-Year 2020 Financial Results on March 1, 2021

Jan 21, 2021: Amicus Therapeutics announces presentations and posters at the 17th Annual WORLDSymposium™ 2021

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Amicus Therapeutics Inc, Key Facts
Amicus Therapeutics Inc, Key Employees
Amicus Therapeutics Inc, Key Employee Biographies
Amicus Therapeutics Inc, Major Products and Services
Amicus Therapeutics Inc, History
Amicus Therapeutics Inc, Other Locations
Amicus Therapeutics Inc, Subsidiaries
Amicus Therapeutics Inc, Key Competitors
Amicus Therapeutics Inc, Ratios based on current share price
Amicus Therapeutics Inc, Annual Ratios
Amicus Therapeutics Inc, Annual Ratios (Cont...1)
Amicus Therapeutics Inc, Annual Ratios (Cont...2)
Amicus Therapeutics Inc, Interim Ratios
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Amicus Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Amicus Therapeutics Inc, Performance Chart (2016 - 2020)

Amicus Therapeutics Inc, Ratio Charts

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Amicus Therapeutics Inc (FOLD) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/A003F789855EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A003F789855EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970